About NanoSyrinx
NanoSyrinx is a Technology company based in Coventry (United Kingdom) founded in 2018 by Nick R Waterfield and Joe Healey. It operates as a drug delivery systems to cell interiors are developed via nanosyringes. It operates in the Technology and Healthcare sectors. NanoSyrinx has raised $21.63 million across 5 funding rounds from investors including Lilly, BioCity and BGF. The company has 17 employees. Its chief executive is Joe Healey. NanoSyrinx offers products and services including Nanosyringe Platform. Its focus areas include Life Sciences, Drug Delivery, Nanoparticle Based and High Tech. Its legal entity is NANOSYRINX LTD. Its competitors include Sirnaomics, Liquidia, Acorda, Genedit and Ensysce and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
NanoSyrinx was established in 2018 in Coventry, United Kingdom, within the biotechnology sector. A genetically encoded drug delivery device is created using nanosyringes to target cell interiors. The system is designed for production and loading through upstream genetics alone, eliminating further preparation steps. Operations center on advancing intracellular drug administration technologies for potential therapeutic applications.
- Headquarters Coventry, United Kingdom
- Employees 17
- Founders Nick R Waterfield, Joe Healey
- SectorsTechnologyHealthcare
- Email••••••••
- Website nanosyrinx.com
- Social LinkedIn X
- Legal Name Nanosyrinx Ltd
- Date of Incorporation 29 Sep, 2018
- Jurisdiction COVENTRY, WEST MIDLANDS, ENGLAND
- Total Equity Funding$21.63M (USD)
in 5 rounds
- Latest Funding Round$13.1M (USD), Series A
Sep 2024
- InvestorsLilly
& 9 more
- Employee Count17
Products & Services of NanoSyrinx
NanoSyrinx offers a comprehensive portfolio of products and services, including Nanosyringe Platform.
Enables targeted delivery of biologic molecules into cells for therapeutic use.
Funding Insights of NanoSyrinx
NanoSyrinx has successfully raised a total of $21.63M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $13.1 million completed in September 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.63M
- Total Rounds 5
- Last Round Series A — $13.1M
- Investors Count 10
All 5 funding rounds of NanoSyrinx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2024 | $13.1M | Series A | – | BGF, Octopus Ventures | |
| Jul 2021 | $8.53M | Seed | – | Octopus Ventures | |
| Sep 2020 | – | Grant | – | – | |
| Sep 2020 | – | Seed | – | M Ventures | |
| Mar 2020 | – | Seed | – | – | – |
10 investors in total: 9 institutional and 1 angel.
Investors in NanoSyrinx
NanoSyrinx has secured backing from 10 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Lilly, BioCity and BGF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early & Growth stage tech & offline focused VC firm funding companies in the UK & Ireland | – | bgf.co.uk | Belfast, United Kingdom | |
Venture capital investment and support for founders in technology and health sectors. | – | octopusventures.com | - | |
Deep tech venture capital firm investing in European and global startups. | – | iqcapital.vc | - | |
Venture capital firm investing in multiple sectors | – | m-ventures.com | Amsterdam, Netherlands | |
Life Science focused startup accelerator and incubator | 2002 | biocity.co.uk | Nottingham, United Kingdom | |
Early-stage innovations are funded by UKI2S across key sectors. | – | ukinnovationscienceseedfund.co.uk | Manchester, United Kingdom | |
- | – | midlandsinnovation.org.uk | - | |
Offers medical advisory services for the life science and biopharma industries. | 2014 | meltwind.co.uk | Cambridge, United States | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | lilly.com | United States | |
JM Jonathan Milner | British angel investor, founder of Abcam, active in biotech and life sciences. | – | unknown_c7adcbdbe1ef4de58 | - |
Investor details for NanoSyrinx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NanoSyrinx
17 people are tracked at NanoSyrinx (6 in leadership, 5 in board & advisors, 6 in team); the tracked headcount is 17.
| Name | Role | Group |
|---|---|---|
Nick R Waterfield | Co-Founder | Leadership |
Joe Healey | Co-Founder & CEO | Leadership |
Marie McAvoy | Chief Scientific Officer | Leadership |
Joseph Healey | CEO & Co-Founder | Leadership |
Bauke Anninga | Director | Leadership |
James Lapworth | Chief Business Officer | Leadership |
Jane Dancer | Non-Executive Director | Board & advisors |
Pete Charlton | Scientific Advisor | Board & advisors |
Andy Topping | Scientific Advisor | Board & advisors |
Stephen Taylor | Chairman | Board & advisors |
Nicholas Waterfield | Scientific Advisor & Co-Founder | Board & advisors |
Hasan M Khan | Scientist I | Team |
Kiran Chintakayala | Associate Principal Scientist (protein Engineering) | Team |
Callum Tebbatt | Senior Scientist | Team |
Farzaneh Ghanavati | Office Manager & Executive Assistant | Team |
Fiona Okonjo | Staff Scientist | Team |
Sabine Bowman-Grahl | Principal Scientist - Protein Production Lead | Team |
Complete people profiles for NanoSyrinx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NanoSyrinx
3 dated milestones of NanoSyrinx across 6 years, from founding to its latest funding, stage changes and deals.
- Founded NanoSyrinx is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $13.1M.
Competitors of NanoSyrinx
NanoSyrinx has 9 listed competitors in our database, 9 of them funded. They include Sirnaomics, Liquidia, Acorda, Genedit and Ensysce, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sirnaomics.com | 2007 | Gaithersburg, United States | $267M | 88 | RNA-based therapeutics for cancer and fibrosis are developed. | |
| liquidia.com | 2004 | United States | $75.3M | 63 | Engineered particles & films for life and material sciences applications | |
| acorda.com | 1995 | Ardsley, United States | $66.5M | 109 | Engaged in the development and commercialization of therapies that improve neurological function. | |
| genedit.com | 2016 | Berkeley, United States | $93.5M | 34 | Genetic medicines are delivered using polymer nanoparticle platforms. | |
| ensysce.com | 2008 | Houston, United States | $2.5M | – | Drug delivery solutions via single-walled carbon nanotubes are offered. | |
| arcturusrx.com | 2013 | San Diego, United States | $1.3M | 337 | RNAi technologies are developed for treating rare orphan diseases. | |
| clene.com | 2012 | Salt Lake, United States | $59.1M | 99 | Nanotechnology-based therapeutics for cancer and auto-immune disorders are developed. | |
| erydel.com | 2007 | Milan, Italy | $31.7M | – | Erythrocyte encapsulation systems for drug delivery are developed. | |
| viaqua-t.com | 2014 | Rehovot, Israel | $12.55M | – | RNAi drug delivery technology is developed for aquaculture disease prevention. |
Detailed competitors of NanoSyrinx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Nanotechnology
10 companies that operate in the same segment as NanoSyrinx (Nanotechnology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Developer of technologies for analysis of genetic variation and function | 1993 | San Diego, California, United States | USD 28 M | USD 1.44 M | 29 | |
RNA interference-based therapeutics are developed for multiple disorders. | 2002 | Cambridge, Massachusetts, United States | USD 17 M | USD 3.71 B | 2,230 | |
Technology tools and systems for molecular scale are developed. | 1959 | Abingdon, Oxfordshire, United Kingdom | – | USD 648.1 M | – | |
Aerogel-based thermal insulation solutions are provided for energy conservation. | 2001 | United States | USD 198.35 M | USD 271.1 M | 554 | |
Nanotech-based electrode materials for supercapacitors are provided. | 2009 | Boston, Massachusetts, United States | USD 163.32 M | – | 66 | |
Instrument systems and software for single-molecule real-time sequencing are developed. | 2004 | Menlo Park, California, United States | USD 395 M | USD 160 M | 575 | |
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | – | 35 | |
Conductive nanocoatings are delivered via atomic layer deposition technology. | 2013 | Boulder, Colorado, United States | USD 202.75 M | – | – | |
RNA therapeutics for hematology and cardiovascular diseases are developed. | 1999 | London, England, United Kingdom | – | USD 559 K | 116 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nanosyrinx
Complete news archive for NanoSyrinx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NanoSyrinx
NanoSyrinx was founded in 2018 and raised its 1st funding round 2 years after it was founded.
NanoSyrinx is headquartered in Coventry, United Kingdom.
Joe Healey is the current CEO of NanoSyrinx. They have also founded this company.
NanoSyrinx is a funded company, having raised a total of $21.63M across 5 funding rounds to date.
NanoSyrinx has 17 employees.
NanoSyrinx was established in 2018 in Coventry, United Kingdom, within the biotechnology sector. A genetically encoded drug delivery device is created using nanosyringes to target cell interiors. The system is designed for production and loading through upstream genetics alone, eliminating further preparation steps. Operations center on advancing intracellular drug administration technologies for potential therapeutic applications.
NanoSyrinx's top competitors include Sirnaomics, Arcturus Therapeutics and Acorda.
NanoSyrinx offers Nanosyringe Platform.
NanoSyrinx has 10 investors. Key investors include Lilly, BioCity, BGF, Octopus Ventures, and IQ Capital.
NanoSyrinx operates through Nanosyrinx Ltd.